<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975843</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AA1-15</org_study_id>
    <secondary_id>2016-001088-35</secondary_id>
    <nct_id>NCT02975843</nct_id>
  </id_info>
  <brief_title>Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients</brief_title>
  <official_title>Open Label, Uncontrolled, Non-randomized, Single Dose, Scintigraphic Study to Investigate Lung Deposition of Inhaled 99mTc Radiolabelled CHF5993 pMDI in Healthy Volunteers, Asthmatic and COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the lung deposition and distribution pattern of
      Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide using a
      Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled CHF
      5993 Administered via pMDI in healthy volunteers, asthmatic and COPD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Actual">April 11, 2017</completion_date>
  <primary_completion_date type="Actual">March 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrapulmonary Lung deposition expressed as % of nominal dose</measure>
    <time_frame>Immediately after dosing</time_frame>
    <description>Calculated using the individual Gamma camera images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of lung deposition</measure>
    <time_frame>Immediately after dosing</time_frame>
    <description>Calculated using the individual Gamma camera images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrathoracic deposition</measure>
    <time_frame>Immediately after dosing</time_frame>
    <description>Calculated using the individual Gamma camera images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled activity</measure>
    <time_frame>Immediately after dosing</time_frame>
    <description>Calculated using the individual Gamma camera images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP/B17MP, Formoterol, and GB Area under curve (AUC) 0-t</measure>
    <time_frame>the area under the plasma concentration-time curve from 0 to the last quantifiable concentration. Over 24h</time_frame>
    <description>Calculated through plasma samples for PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP/B17MP, Formoterol, and GB Area under curve (AUC) 0-30min</measure>
    <time_frame>area under the plasma concentration-time curve from 0 to 30 min post-dose</time_frame>
    <description>Calculated through plasma samples for PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP/B17MP, Formoterol, and GB area under the curve (AUC) 0-∞</measure>
    <time_frame>area under the curve extrapolated to infinity over 24h</time_frame>
    <description>Calculated through plasma samples for PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP/B17MP, Formoterol, and GB Peak Plasma Concentration (Cmax)</measure>
    <time_frame>the value of the maximum plasma concentration will be obtained directly from the experimental data without interpolation. Over 24h</time_frame>
    <description>Calculated through plasma samples for PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP/B17MP, Formoterol, and GB tmax</measure>
    <time_frame>time of the maximum plasma concentration will be obtained directly from the experimental data without interpolation. Over 24h</time_frame>
    <description>Calculated through plasma samples for PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP/B17MP, Formoterol, and GB t½</measure>
    <time_frame>the terminal (apparent elimination) half-life over 24h</time_frame>
    <description>Calculated through plasma samples for PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lung function assessment</measure>
    <time_frame>Over 24 h post dose</time_frame>
    <description>Calculated using spirometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF5993</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium</intervention_name>
    <description>single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)</description>
    <arm_group_label>CHF5993</arm_group_label>
    <other_name>CHF5993 pMDI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all subjects:

          1. Subject's written informed consent obtained prior to any study-related procedure

          2. Body mass index (BMI) between 18 and 32 kg/m2

          3. Ability to understand the study procedures and the risks involved and ability to be
             trained to use the devices correctly at screening and pre-dose.

          4. Normal vital signs (Diastolic BP 60-90 mmHg, Systolic BP 90-140 mmHg or 90-150 if &gt;45
             yrs) at screening and pre-dose.

          5. 12-lead digitalised ECG considered as normal: 60 ≤ heart rate ≤ 100 bpm, 120 ms ≤ PR
             ≤210 ms, QRS ≤ 120 ms, QTcF ≤ 450 ms (male) and ≤ 470 ms (female) at screening and
             pre-dose

          6. Males fulfilling one of the following criteria:

               1. Males with non-pregnant Women of childbearing potential (WOCBP) partners: they
                  and/or their partner of childbearing potential must be willing to use a highly
                  effective birth control method in addition to the male condom from the signature
                  of the informed consent and until 90 days after the follow-up visit. Subjects
                  must not donate sperm during the study and for 90 days after the follow-up visit
                  or

               2. Males with pregnant WOCBP partner: they must be willing to use male contraception
                  (condom) from the signature of the informed consent and until 90 days after the
                  follow-up visit. Subjects must not donate sperm during the study and for 90 days
                  after the follow-up visit or

               3. Non-fertile male subjects (contraception is not required in this case) or

               4. Males with partner not of childbearing potential (contraception is not required
                  in this case).

          7. WOCBP fulfilling one of the following criteria:

               1. WOCBP with fertile male partners: they and/or their partner must be willing to
                  use a highly effective birth control method with low user dependency from the
                  signature of the informed consent and until 30 days after the follow-up visit or

               2. WOCBP with non-fertile male partners (contraception is not required in this
                  case).

          8. Female patients of non-childbearing potential defined as physiologically incapable of
             becoming pregnant (i.e. post-menopausal or permanently sterile). Tubal ligation or
             partial surgical interventions are not acceptable. If indicated, as per investigator's
             request, post-menopausal status may be confirmed by follicle-stimulating hormone
             levels (according to local laboratory ranges)

             Additional Inclusion criteria for Healthy /volunteers and Asthmatic patients:

          9. Males and females aged 18-55

         10. Non- or Ex-smokers who smoked &lt; 5 pack years (pack-years = number of cigarette packs
             per day times the number of years) and stopped smoking &gt; 1 year

             Additional Inclusion Criteria only for Healthy volunteers:

         11. Lung function within normal limits: FEV1 ≥ 80% of predicted (according to the Global
             Lung Function Initiative, ERS Task Force Lung Function Reference Vales) and FEV1/FVC
             ratio &gt; 0.70 at screening

             Additional Inclusion Criteria only for Asthmatic patients:

         12. Pre-bronchodilator 60% ≤ FEV1 ≤ 80% of predicted (according to the Global Lung
             Function Initiative, ERS Task Force Lung Function Reference Vales) and FEV1/FVC ratio
             &gt; 0.70 at screening. If this criterion is not met at Screening, the test can be
             repeated once before Day -1.

         13. Positive reversibility test as defined by an increase in FEV1 ≥ 12% and at least 200
             ml compared to the initial value 20-30 minutes after inhalation of 400 μg Salbutamol
             at screening. If this criterion is not met at Screening, the test can be repeated once
             before Day -1.

             Additional Inclusion Criteria only for COPD patients:

         14. Males and females aged 40-75

         15. Current or ex- smokers (stopped smoking &gt; 1 year ) minimum smoking history of 10
             pack-years (packyears = number of cigarette packs per day times the number of years)

         16. 30% ≤ FEV1 &lt; 50% of predicted and FEV1/FVC &lt; 0.70 after inhalation of 400 μg
             Salbutamol. If this criterion is not met at Screening, the test can be repeated once
             before Day -1.

        Exclusion Criteria for all subjects:

          1. Pregnant or lactating women

          2. Documented history of drug abuse (within 12 months before screening) and/or positive
             urine drug test at screening and/or at treatment period

          3. History of hypersensitivity to M3 Antagonists, β2-agonist, corticosteroids or any of
             the excipients contained in any of the formulations used in the trial;

          4. Any clinically relevant abnormal laboratory value at screening suggesting an unknown
             disease and requiring further clinical investigation or which may impact the safety of
             the subject or the evaluation of the result of the study according to the
             investigator's judgment

          5. Clinically relevant and uncontrolled hepatic, gastrointestinal, renal, genitourinary,
             endocrine, metabolic neurologic, or psychiatric disorder that may interfere with
             successful completion of this protocol

          6. Serology at the screening positive to HIV1 or HIV2 and positive results for Hepatitis
             which indicates acute or chronic Hepatitis B (i.e. positive HB surface antigen HBsAg
             positive and/or positive HB core antibody anti-HBc) or Hepatitis C (HCV antibody);

          7. Subjects with history of sustained and non-sustained cardiac arrhythmias (ECG
             demonstrated) and subjects with a family history of sudden cardiac death

          8. Subjects who have cardiovascular condition such as, but not limited to unstable
             ischemic heart disease, NYHA Class III/IV left ventricular failure, acute ischemic
             heart disease in the last year prior to study screening, which may impact the safety
             of the subject or the evaluation of the result of the study according to the
             investigator's judgment

          9. Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck
             obstruction that in the opinion of the investigator would prevent use of
             anticholinergic agents&quot;

         10. Significant blood loss ≥ 400 ml within 3 months prior screening and between screening
             and Day 1;

         11. Participation in another clinical trial with an investigational drug in the previous 3
             months before the administration of the study drug; a longer and more appropriate time
             could be considered by the principal investigator based on the elimination of the
             half-life and/or long term toxicity of the previous investigational drug;

         12. Radiation exposure, including that from the present study, excluding background
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study.

         13. Unsuitable veins for repeated venipuncture

         14. Any not allowed concomitant medication

             Additional Exclusion criteria for Healthy volunteers and Asthmatic patients:

         15. Current use of any nicotine or nicotine replacement product

             Additional Exclusion criteria for Asthmatic and COPD patients:

         16. Use of systemic steroids in the 4 weeks prior to screening and between screening and
             Day 1 (injectable depot steroids 6 weeks)

         17. Life-threatening/unstable respiratory status including upper or lower respiratory
             tract infection, within the previous 30 days before screening and between screening
             and Day 1

         18. Requirement for continuous oxygen therapy (supplemental oxygen not exceeding 2 l/min,
             at night only and/or during exercise is allowed)

             Additional Exclusion criteria only for asthmatic patients:

         19. Change in dose or type of any medications for asthma within 4 weeks prior to the
             screening visit

         20. Asthma exacerbation within the 4 weeks prior screening and between screening and Day 1

         21. History of COPD or any chronic respiratory disease other than Asthma

             Additional Exclusion criteria only for COPD patients:

         22. Change in dose or type of any medications for COPD within 4 weeks prior to the
             screening visit

         23. COPD exacerbation within the 4 weeks prior screening and between screening and Day 1

         24. History of asthma or any chronic respiratory disease other than COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

